Published in Virchows Arch on August 02, 2011
Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer (2013) 0.99
HER2/neu testing in primary colorectal carcinoma. Br J Cancer (2014) 0.94
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care (Basel) (2013) 0.90
Development and characterisation of a 3D multi-cellular in vitro model of normal human breast: a tool for cancer initiation studies. Oncotarget (2015) 0.89
Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. Asia Pac J Clin Oncol (2014) 0.83
Quality assurance in clinical trials-the role of pathology. Virchows Arch (2015) 0.79
[Round robin test for detection of genomic aberrations in non-Hodgkin lymphoma by in situ hybridization]. Pathologe (2013) 0.78
Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. PLoS One (2013) 0.78
HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol (2017) 0.75
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Mod Pathol (2016) 0.75
[Receptor detection in breast cancer. A decade of quality assurance trials in German-speaking pathology]. Pathologe (2011) 0.75
[HER2 testing in gastric cancer : Results of a meeting of German experts]. Pathologe (2016) 0.75
[Translational research and diagnostics for breast cancer]. Pathologe (2012) 0.75
Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry. Virchows Arch (2015) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol (2009) 5.66
HER-2 testing in breast cancer using parallel tissue-based methods. JAMA (2004) 4.60
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst (2002) 3.99
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer (2004) 3.50
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol (2002) 3.05
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol (2002) 1.99
Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol (2002) 1.62
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ (2007) 1.53
Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch (2008) 1.38
The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. Am J Surg Pathol (2011) 1.09
Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med (2006) 1.04
Trastuzumab for early breast cancer: current status and future directions. Clin Adv Hematol Oncol (2007) 1.01
Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol (2007) 0.95
Implementation of External Quality Assurance Trials for Immunohistochemically Determined Breast Cancer Biomarkers in Germany. Breast Care (Basel) (2008) 0.94
First Revision of the German S3 Guideline 'Diagnosis, Therapy, and Follow-Up of Breast Cancer' Breast Care (Basel) (2008) 0.93
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol (2009) 0.88
Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer. Breast J (2005) 0.86
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med (2009) 7.53
Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology (2012) 3.28
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol (2002) 1.99
Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol (2002) 1.71
Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury. Am J Pathol (2003) 1.69
Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol (2002) 1.68
Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina, Inc. BMC Res Notes (2012) 1.59
"Hypoxia-induced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) mRNA - a mechanism involved in SERPINE1 (PAI-1) overexpression". J Transl Med (2010) 1.59
Undifferentiated embryonal sarcoma of the liver in adults. Cancer (2008) 1.56
KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. Int J Cancer (2008) 1.52
Aberrant proplatelet formation in chronic myeloproliferative neoplasms. Leuk Res (2010) 1.52
Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology (2011) 1.49
Congenital phimosis in patients with and without lichen sclerosus: distinct expression patterns of tissue remodeling associated genes. J Urol (2012) 1.41
Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant (2003) 1.40
Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med (2013) 1.39
Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch (2008) 1.38
Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology (2002) 1.38
Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology (2012) 1.37
Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant (2005) 1.37
MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat (2011) 1.34
JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol (2009) 1.28
Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int (2005) 1.27
Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer (2011) 1.27
Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest (2002) 1.26
Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem (2007) 1.25
Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. Clin Chem (2006) 1.24
High frequency of epithelial chimerism in liver transplants demonstrated by microdissection and STR-analysis. Hepatology (2002) 1.24
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol (2011) 1.23
Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol (2003) 1.19
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol (2009) 1.17
Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat (2006) 1.16
MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer (2011) 1.15
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica (2011) 1.15
Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant (2012) 1.15
Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res (2005) 1.14
High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res (2006) 1.13
Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol (2012) 1.12
Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development. J Pathol (2005) 1.12
Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS One (2012) 1.11
Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker. Int J Cancer (2013) 1.09
Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res (2002) 1.09
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol (2003) 1.09
Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol (2008) 1.09
IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch (2003) 1.06
MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. Platelets (2009) 1.05
Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology. BMC Biotechnol (2008) 1.05
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol (2011) 1.04
Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A (2013) 1.02
Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer. J Pathol (2009) 1.01
Systematic cross-validation of 454 sequencing and pyrosequencing for the exact quantification of DNA methylation patterns with single CpG resolution. BMC Biotechnol (2011) 1.00
Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res (2010) 1.00
Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol (2011) 1.00
Fibroblasts of recipient origin contribute to bronchiolitis obliterans in human lung transplants. Am J Respir Crit Care Med (2006) 0.99
Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. Int J Oncol (2005) 0.99
Recipient-derived neoangiogenesis of arterioles and lymphatics in quilty lesions of cardiac allografts. Transplantation (2007) 0.98
Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology (2005) 0.98
Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer (2013) 0.97
Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol (2005) 0.97
Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma. Mod Pathol (2008) 0.96
Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. Br J Haematol (2005) 0.96
Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PLoS One (2010) 0.96
Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*. Eur J Haematol (2009) 0.95
Amplification of mRNA from laser-microdissected single or clustered cells in formalin-fixed and paraffin-embedded tissues for application in quantitative real-time PCR. Diagn Mol Pathol (2008) 0.95
Obliterative airway remodelling in transplanted and non-transplanted lungs. Virchows Arch (2010) 0.95
Implementation of External Quality Assurance Trials for Immunohistochemically Determined Breast Cancer Biomarkers in Germany. Breast Care (Basel) (2008) 0.94
Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc Natl Acad Sci U S A (2004) 0.94
Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer (2010) 0.94
B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol (2006) 0.94
Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis. Br J Haematol (2009) 0.93
Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem (2009) 0.93
Assessment of differentiation and progression of hepatic tumors using array-based comparative genomic hybridization. Clin Gastroenterol Hepatol (2006) 0.93
Role of epigenetic changes in hematological malignancies. Ann Hematol (2003) 0.92
Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions. Mod Pathol (2008) 0.92
Reliability of lymphoma classification in bone marrow trephines. Br J Haematol (2002) 0.92
Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br J Haematol (2004) 0.92
Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol (2006) 0.91
Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn (2006) 0.91
Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res (2005) 0.91
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet (2005) 0.90
Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol (2005) 0.90
Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation (2013) 0.89
Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol (2005) 0.89
Local complement C3 expression is upregulated in humoral and cellular rejection of renal allografts. Am J Transplant (2005) 0.89
Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosomes Cancer (2012) 0.88
Absence of p21(CIP 1), p27(KIP 1) and p 57(KIP 2) methylation in MDS and AML. Leuk Res (2005) 0.88
Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats. Am J Pathol (2011) 0.88
IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes. Lab Invest (2012) 0.87
Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res (2009) 0.87
Standardised fluorescence in situ hybridisation in cytological and histological specimens. Virchows Arch (2005) 0.87
HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma. BMC Cancer (2014) 0.87